Intracellular Bacteria and Protozoa - Intracellular Delivery: Fundamentals and Applications - page 799

Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Disc 2: 347-360
Duncan K, Barry CE III (2004) Prospects for new antitubercular drugs. Curr Opinion Microbiol
7: 460-465
Duval X, Leport C (2001) Toxoplasmosis in AIDS. Curr Treatment Options Infect Dis 3:
113-128
Duzgunes N, Perumal VK, Kesavalu L, Goldstein JA, Debs RJ, Gangadharam PRJ (1988)
Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellu-
lare complex infection in beige mice. Antimicrob Agents Chemother 32: 1404-1411
Dye C (2006) Global epidemiology of tuberculosis. Lancet 367: 938-940
Easmon CSF, Crane JP (1985 a) Uptake of ciprofloxacin by macrophages. J Clin Pathol 38:
442- 444
Easmon CSF, Crane JP (1985 b) Uptake of ciprofloxacin by human neutrophils. J Antimicrob
Chemother 16: 67- 73
Ebert SC (2004) Application of pharmacokinetics and pharmacodynamics to antibiotic selection.
PharmD, BCPS 29: 244-252
Ehlers S, Bucke W, Leitzke S, Smith D, Fortmann L, Hänsch H, Hahn H, Bancroft G, Müller R
(1996) Liposomal amikacin for treatment of experimental Mycobacterium avium infections
mimicking clinically relevant disease. Int J Med Microbiol Virol Parasitol Infect Dis 284:
218- 231
El-On J, Livshin R, Even-Paz Z, Hamburger D, Weinrauch L (1986) Topical treatment of cutane-
ous leishmaniasis. J Invest Dermatol 87: 284-288
El-On J, Halevy S, Grunwald MH, Weinrauch L (1992) Topical treatment of Old World cutaneous
leishmaniasis caused by Leishmania major : a double-blind control study. J Am Acad Dermatol
27: 227-231
El-Ridy MS, Mostafa DM, Shehab A, Nasr EA, El-Alim SA (2007) Biological evaluation of
pyrazinamide liposomes for treatment of Mycobacterium tuberculosis . Int J Pharm 330:
82-88
Emerich DF, Thanos CG (2006) The pinpoint promise of nanoparticle-based drug delivery and
molecular diagnosis. Biomol Eng 23: 171-184
Enderlin G, Morales L, Jacobs RF, Cross LT (1994) Streptomycin and alternative agents for the
treatment of tularaemia; review of literature. Clin Infect Dis 19: 42- 47
European Science Foundation (2005) Nanomedicine. An ESF-European Medical Research
Councils (EMRC) Forward Look report. http://www.nanopharmaceuticals.org/files/
nanomedicine.pdf
Evrard B, Bertholet P, Gueders M, Flament MP, Piel G, Delattre L, Gayot A, Leterme P, Foidart
JM, Cataldo D (2004) Cyclodextrins as a potential carrier in drug nebulization. J Control
Release 96: 403-410
Fang J, Nakamura H, Maeda H (2010) The EPR effect: Unique features of tumor blood vessels
for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug
Del Rev [Epub ahead of print]
Fattal E, Youssef M, Couvreur P, Andremont A (1989) Treatment of experimental Salmonellosis
in mice with ampicillin-bound nanoparticles. Antimicrob Agents Chemother 33: 1540-1543
Fierer J, Hatlen L, Lin JP, Estrella D, Mihalko P, Yau-Young A (1990) Successful treatment using
gentamicin liposomes of Salmonella Dublin infections in mice. Antimicrob Agents Chemother
34 (2): 343-348
Finlay BB (1994) Molecular and cellular mechanisms of Salmonella pathogenesis. Curr Top
Microbiol 192: 163-185
Finlay WH, Wong JP (1998) Regional lung deposition of nebulized liposome-encapsulated cipro-
floxacin. Int J Pharm 167: 121-127
Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA (1991) Live vaccine strain of
Francisella tularensis : infection and immunity in mice. Infect Immun 59: 2922-2928
Fortier AH, Leiby DA, Narayanan RB, Asafoadjei E, Crawford RM, Nacy CA, Meltzer MS,
(1995) Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compart-
ment provides essential iron required for growth. Infect Immun 63: 1478-1483